Skip to content

Testicular Sperm Aspiration (TESA) vs. Microfluidic Sperm Separation (MSS)

Testicular Sperm Aspiration (TESA) vs. Microfluidic Sperm Separation (MSS) in Couples With High Sperm DNA Fragmentation Undergoing ICSI: Which Approach is Better

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05866484
Acronym
TESA vs Zymot
Enrollment
280
Registered
2023-05-19
Start date
2023-05-10
Completion date
2024-05-31
Last updated
2024-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Azoospermia, Infertility, Male, Reproductive Disorder

Brief summary

Normal embryonic development relies on the correct transmission of genetic information, and sperm DNA plays a crucial part in this process. Causes of poor sperm DNA integrity include unhealthy lifestyles such as smoking and exposure to gonadotoxins, as well as, obesity, varicoceles, infections, advanced paternal age and systemic disorders. An increase in DNA fragmentation in sperm has been linked to lower fertilisation rate, poorer quality embryos, lower pregnancy rate, and high miscarriages rate. The best way for sperm selection and processing in assisted reproductive technologies (ART) should be noninvasive and cost-effective. It should also make it possible to identify high-quality spermatozoa and produce more favorable results in terms of pregnancy and live birth rates.7 Meanwhile, the microfluidic sperm separation technology is a less expensive and less invasive alternative. This method allows for the selection of motile sperm that have a normal morphology, low levels of reactive oxygen species (ROS), and low DFI

Interventions

None listed

Sponsors

Clinique Ovo
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men with high DNA fragmentation (\>20%) undergoing TESA-ICSI or Zymot-ICSI

Exclusion criteria

* Spouse with advanced maternal age (\> 40 years) * Egg donation cycle

Design outcomes

Primary

MeasureTime frameDescription
Clinical Pregnancy Rateapproximately 8 weeksCompare clinical pregnancy rate in couples with high Sperm DNA fragmentation

Secondary

MeasureTime frameDescription
Number of utilizable blastocysts obtainedApproximately 20 daysCompare the number of utilizable embryos obtained in couples using TESA-ICSI vs Zymot-ICSI

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026